Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Research
ESMO Open
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study
Cancer Research
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond
The New England Journal of Medicine
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Nature Medicine
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Molecular Cancer Therapeutics
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Cancer Research
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer
Cancer
TRKing sarcomas for precision medicine: Seek, and ye shall find!
Cell Reports Medicine
Clinical development and management of adverse events associated with FGFR inhibitors
Future Oncology
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer